Current treatments in neurology: stroke.
There have been major advances in stroke treatment based on robust evidence from large clinical trials. This review covers both acute treatment and secondary prevention. Thrombolysis is now established as a therapy for ischaemic stroke presenting within 3 hours, and the possibility of extending the time window and refining the selection of suitable patients, is being addressed in further trials. Anticoagulants are of proven benefit in cardioembolic stroke, and particularly atrial fibrillation. For prevention of other stroke subtypes antiplatelet agents appear to have a better risk-benefit ratio. Evidence for the use of dual antiplatelet therapy, including the recent MATCH study, are discussed. Carotid endarterectomy is of proven benefit in patients with>70% symptomatic stenosis. Recent analysis has emphasised the importance of operating as soon after symptom onset as possible. Operating on asymptomatic carotid stenosis remains controversial; even after the recent Asymptomatic Carotid Surgery Trial which showed that by operating on 32 people one disabling stroke or death could be prevented over a 5 years period.
Markus
Hugh S
HS
Clinical Neuroscience, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. h.markus@sghms.ac.uk
D001241:Aspirin / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009462:Neurology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D009493:Neurosurgery / Q000379:methods; D015607:Stents; D020521:Stroke / Q000473:pathology / Q000628:therapy*; D015912:Thrombolytic Therapy / Q000379:methods
D018696:Neuroprotective Agents; D006493:Heparin; D001241:Aspirin
Lancet. 2004 Mar 6;363(9411):768-74
15016487
Lancet. 2001 Jun 2;357(9270):1729-37
11403808
Lancet. 1996 Nov 16;348(9038):1329-39
8918275
Cochrane Database Syst Rev. 2002;(1):CD000197
11869570
N Engl J Med. 2000 Jan 20;342(3):145-53
10639539
Lancet. 2004 May 8;363(9420):1491-502
15135594
BMJ. 2004 Feb 28;328(7438):514-7
14988196
Ann Neurol. 1997 Dec;42(6):857-65
9403477
Lancet. 2002 Mar 23;359(9311):995-1003
11937178
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
Lancet. 1998 May 9;351(9113):1379-87
9593407
N Engl J Med. 1991 Aug 15;325(7):445-53
1852179
Cochrane Database Syst Rev. 2003;(3):CD000213
12917889
Lancet. 2004 Jul 24-30;364(9431):331-7
15276392
JAMA. 2002 Nov 20;288(19):2411-20
12435254
Ann Neurol. 2002 Jul;52(1):20-8
12112043
N Engl J Med. 1998 Nov 12;339(20):1415-25
9811916
JAMA. 2000 Dec 13;284(22):2901-6
11147987
Cerebrovasc Dis. 1999 Jul-Aug;9(4):193-201
10393405
Stroke. 2004 Feb;35(2):363-4
14757880
J Neurol Sci. 1996 Nov;143(1-2):1-13
8981292
JAMA. 1995 May 10;273(18):1421-8
7723155
Acta Neurochir Suppl. 2003;86:441-3
14753482
BMJ. 2000 Feb 26;320(7234):549
10688561
Am J Cardiovasc Drugs. 2003;3(2):87-94
14727935
BMJ. 2002 Jan 12;324(7329):71-86
11786451
N Engl J Med. 2001 Nov 15;345(20):1444-51
11794192
BMJ. 2004 Feb 7;328(7435):326
14744823
Lancet. 1997 May 31;349(9065):1569-81
9174558
Lancet. 1993 Nov 20;342(8882):1255-62
7901582
Lancet. 2004 Feb 7;363(9407):439-45
14962524
Lancet. 2001 Sep 29;358(9287):1033-41
11589932
Lancet. 2004 Mar 20;363(9413):915-24
15043958
BMJ. 2004 Feb 14;328(7436):369
14962873
J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):353-61
14966145
Ann Intern Med. 1999 Oct 5;131(7):492-501
10507957
Lancet. 2003 Jun 14;361(9374):2005-16
12814710
Stroke. 2003 Aug;34(8):e138-40
12855835
Cerebrovasc Dis. 2004;17 Suppl 1:81-8
14694285
Lancet. 1997 Jun 7;349(9066):1641-9
9186381
Stroke. 2004 Feb;35(2):389-91
14757889